
Onyx Scientific
Exhibiting with the UK delegation at booth #30
Onyx Scientific is the CDMO division of Ipca Laboratories, offering small molecule drug substance development and manufacturing services. Our MHRA-licensed sites in the UK offer early development of candidate APIs and manufacturing for clinical phases through to commercial supply. Dedicated solid-state and analytical chemistry teams expedite development activities at Onyx but are also available to provide full-service outsourced projects to complement or support your in-house campaigns. With a wealth of early development experience and success, our pragmatic, fit-for-purpose approach focuses on rapid process development and a view to future GMP campaigns. Where required, scale-up through Phase II towards commercial manufacture is retained either at our UK site or within the Group through transfer to our sister sites and colleagues in the USA and India.
Dr Chris Atherton
Commercial ManagerDr Julian Northen
Solid State ManagerRoslin Cell Therapies Limited
Exhibiting with the UK delegation at booth #30
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and manufacturing the first-ever US FDA-approved CRISPR-based gene therapy CASGEVY™. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide.
Mr Andy Paterson
Senior Business Development Manager
SGS Quay Pharma
Exhibiting with the UK delegation at booth #30
WORLD-LEADING INNOVATIVE FORMULATION CDMO
We are a Contract Development Manufacturing Organisation (CDMO). We specialise in the development of innovative new entities for biotech companies, globally.